United States Patent 9,457,093: Claim Scope, Patent Strength, Exclusivity, and Generic Entry Analysis
U.S. Patent No. 9,457,093 protects a spray-dried amorphous solid dispersion of a specific quinazoline ErbB2 inhibitor with PVP-VA, together with tablets, excipient-defined compositions, a sodium-bicarbonate formulation, a breast-cancer treatment method, and a spray-drying process. The estate is formulation- and manufacturing-focused rather than a broad composition-of-matter patent.
The principal infringement risk is a product containing the specified active ingredient in an amorphous PVP-VA dispersion. A generic or follow-on manufacturer that uses a different polymer, a crystalline API, or a non-spray-drying process may avoid literal infringement of claim 1 and claim 24, although dependent formulation and method claims require separate analysis. The supplied claims do not establish the patent’s assignee, priority chain, terminal disclaimers, patent-term adjustment, Orange Book listing, FDA approval status, or litigation history.
What does U.S. Patent 9,457,093 protect?
The patent protects a defined pharmaceutical technology built around five elements:
- A specific quinazoline active pharmaceutical ingredient.
- The active ingredient in amorphous form.
- PVP-VA as the dispersion polymer.
- Optional tablet compositions containing specified excipient classes.
- Spray drying as the claimed manufacturing route.
The core independent claim is claim 1:
A solid dispersion comprising amorphous N4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and PVP-VA.
The claim does not cover every formulation of the active ingredient. It requires the active ingredient to be amorphous and the dispersion polymer to be PVP-VA. “Comprising” makes the claim open-ended, so additional excipients or processing aids do not necessarily avoid infringement.
The compound itself is not claimed in the supplied claims as a free-standing chemical entity, salt, polymorph, dosage form, or therapeutic agent. The patent therefore does not, based on these claims alone, provide a composition-of-matter monopoly over the active ingredient.
How broad is claim 1 of U.S. Patent 9,457,093?
Claim 1 is narrow in chemical identity and polymer selection but potentially broad in formulation architecture.
| Claim limitation |
Scope effect |
| Specific quinazoline compound |
Excludes structurally different ErbB2 inhibitors |
| Amorphous active ingredient |
Excludes purely crystalline formulations |
| Solid dispersion |
Requires the API to be dispersed in a solid matrix or equivalent solid carrier system |
| PVP-VA |
Excludes formulations using only HPMC, HPMC-AS, Soluplus, PVP, or another polymer |
| “Comprising” |
Permits additional excipients and ingredients |
PVP-VA is commonly understood as copovidone, a vinylpyrrolidone-vinyl acetate copolymer. A product using copovidone under a different commercial name would remain exposed if the material is chemically equivalent to PVP-VA.
The claim does not specify:
- The molecular-weight grade of PVP-VA.
- The ratio of vinylpyrrolidone to vinyl acetate.
- Particle size.
- Residual solvent.
- Dissolution rate.
- Glass-transition temperature.
- Tablet hardness.
- API salt or solvate status.
- Spray-drying parameters.
- A specific therapeutic dose.
Those omissions increase the practical breadth of claim 1 within the PVP-VA/amorphous-dispersion category.
What do claims 2 through 6 add?
Claims 2 through 6 narrow the solid dispersion by defining API loading and amorphous content.
| Claim |
Added limitation |
Commercial relevance |
| 2 |
API is about 0.1% to about 50% by weight relative to PVP-VA |
Broad loading range |
| 3 |
API is about 5% to about 35% relative to PVP-VA |
More commercially focused range |
| 4 |
API is about 25% to about 35% relative to PVP-VA |
Narrow preferred range |
| 5 |
At least 80% of API is amorphous |
Covers partially crystalline material |
| 6 |
At least 95% of API is amorphous |
Stronger purity limitation |
The percentage language is relative to the dispersion polymer, not necessarily the total finished tablet. For example, an API-to-polymer ratio of 30% means approximately 30 parts API for every 100 parts PVP-VA, subject to how the patent defines the measurement basis.
Claims 5 and 6 raise analytical issues. An accused product may require characterization by powder X-ray diffraction, differential scanning calorimetry, microscopy, spectroscopy, or solid-state quantitation. The patent’s enforceability will depend in part on whether the amorphous percentage can be measured reproducibly and whether the specification provides an enabling and sufficiently definite analytical method. These issues implicate the written-description, enablement, and definiteness requirements of 35 U.S.C. § 112.
What formulations are protected by claims 7 through 22?
Claims 7 through 22 extend protection from the dispersion itself to finished pharmaceutical compositions.
General tablet and pharmaceutical-composition claims
Claim 7 covers a pharmaceutical composition containing the claim 1 dispersion and one or more pharmaceutically acceptable excipients. Claim 8 narrows the composition to a tablet.
Because claim 7 is open-ended, a formulation may fall within its scope even if it contains excipients not expressly identified in later claims. Claim 8 captures conventional oral solid dosage forms but does not specify immediate release, modified release, dosage strength, coating, or tablet geometry.
Excipient-defined compositions
Claims 9 and 10 require the following excipient categories:
- Disintegrant
- Osmogen
- Glidant
- Lubricant
- Binder or filler
Claim 9 uses a binder, while claim 10 substitutes a filler. The stated ranges are:
| Component |
Claim 9 range |
Claim 10 range |
| Solid dispersion |
1% to 70% |
1% to 70% |
| Disintegrant |
0.1% to 20% |
0.1% to 20% |
| Osmogen |
0.1% to 25% |
0.1% to 25% |
| Glidant |
0.1% to 10% |
0.1% to 10% |
| Lubricant |
0.1% to 10% |
0.1% to 10% |
| Binder or filler |
0.1% to 25% |
0.1% to 25% |
Claims 11 through 17 narrow particular excipient levels. Claims 20 and 21 narrow the solid-dispersion content to 25% to 60% and 40% to 60%, respectively. Claim 22 specifies a tablet.
A design-around may be possible by eliminating one required excipient category, using a composition outside the stated ranges, or relying on a different dosage form. That analysis requires testing the product against every limitation of the asserted claim. A formulation that avoids claim 9 may still infringe claim 7 or claim 8.
Sodium-bicarbonate claims
Claims 18 and 19 protect compositions containing the solid dispersion and sodium bicarbonate. Claim 19 specifies 0.1% to 30% sodium bicarbonate and 1% to 70% solid dispersion.
These claims create a separate formulation risk. A product that uses sodium bicarbonate as an alkalizing agent, gas-generating component, pH modifier, or excipient may require review even if it does not use the full excipient profile of claim 9.
Does the patent cover treatment of ErbB2-positive breast cancer?
Claim 23 covers:
A method for the treatment of ErbB2-positive breast cancer comprising administering to a patient a therapeutically effective amount of the claim 1 solid dispersion.
This is a method-of-use claim, not a broad claim to treatment with the active ingredient in every dosage form. The claimed treatment requires administration of the protected solid dispersion.
Potential enforcement targets include:
- A manufacturer that labels the product for ErbB2-positive breast cancer.
- A product label that expressly identifies HER2-positive breast cancer.
- Promotional materials encouraging the patented use.
- A product supplied with instructions that make the claimed use commercially foreseeable.
The claim may be less useful against an ANDA applicant that uses a noninfringing formulation and omits the patented indication, although induced-infringement exposure can depend on the complete label and surrounding conduct under 35 U.S.C. §§ 271(b) and 271(e).
What process is protected by claim 24?
Claim 24 requires:
- Dissolving the specified active ingredient and PVP-VA in a suitable solvent to create a feed solution.
- Evaporating the solvent by spray drying the feed solution to form the solid dispersion.
The process claim is narrower than the product claim because it requires both co-dissolution and spray drying. A manufacturer using hot-melt extrusion, vacuum drying, fluid-bed coating, anti-solvent precipitation, or a separate-feed spray-drying process may have a noninfringement position if the process does not meet the claim construction.
The process claim may be difficult to investigate because manufacturing steps are generally not visible in the finished product. Discovery, regulatory submissions, supplier records, technical due diligence, or process patent disclosures may be needed to establish infringement.
How strong is the patent estate for the active ingredient?
Based on the supplied claims, the patent estate has meaningful formulation coverage but limited standalone chemical coverage.
| Protection category |
Coverage shown by supplied claims |
Relative strength |
| Composition of matter |
Not shown |
None from these claims |
| Amorphous solid dispersion |
API plus PVP-VA |
High within the defined combination |
| API loading |
0.1% to 50%, with narrower subranges |
Moderate to high |
| Amorphous content |
At least 80% or 95% |
Moderate, subject to testing |
| Tablet composition |
Broad excipient claim and narrower profiles |
Moderate |
| Sodium-bicarbonate formulation |
Yes |
Moderate |
| Method of treatment |
ErbB2-positive breast cancer |
Moderate, label-dependent |
| Spray-drying process |
Yes |
Moderate to high if process is used |
| Salt, polymorph, or crystalline API |
Not shown |
None from these claims |
The strongest commercial position is likely claim 1, because it combines the active ingredient, amorphous state, and PVP-VA while allowing additional components. Claims 2 through 6 provide fallback positions if the accused product uses a narrower loading or amorphous-content profile.
When does U.S. Patent 9,457,093 lose exclusivity?
The expiration date cannot be determined reliably from the patent number and claims alone. U.S. patent expiration generally depends on the earliest effective nonprovisional filing date, applicable continuation relationships, patent-term adjustment, patent-term extension, and terminal disclaimers. The governing framework is 35 U.S.C. §§ 154 and 156.
A grant date does not establish the expiration date. A complete term calculation requires the patent’s front-page priority data, continuity statement, USPTO term-adjustment information, and any FDA patent-term-extension record.
The patent may also have limited practical value if:
- The active ingredient never received FDA approval.
- The approved product uses a different formulation.
- The patent was disclaimed, invalidated, canceled, or terminally disclaimed.
- No relevant patent is listed in the FDA Orange Book.
- The commercial product is protected by a later patent with a different expiration date.
What is the Orange Book and Paragraph IV status?
The supplied claims do not establish an Orange Book listing or a Paragraph IV challenge. Orange Book listing is tied to an approved drug application and eligible patents, including patents covering the drug substance, drug product, or approved method of use under FDA rules.
For a small-molecule product, a generic applicant could submit an ANDA with:
- Paragraph I certification if no relevant patent is listed.
- Paragraph II certification if the patent has expired.
- Paragraph III certification accepting delayed approval until expiration.
- Paragraph IV certification alleging that the listed patent is invalid, unenforceable, or not infringed.
A Paragraph IV notice could trigger patent litigation under 35 U.S.C. § 271(e)(2). The 30-month stay mechanism and approval timing would depend on the filing date of the notice, the NDA holder’s response, and the specific Orange Book listing.
No biosimilar pathway is implicated by these claims. The protected molecule is a small-molecule quinazoline compound, so a competing product would generally use the ANDA or, depending on development status, an NDA pathway rather than a biosimilar application under the Public Health Service Act.
Which companies are challenging the patent?
No challenger, litigation, or settlement agreement is established by the supplied claim text. The claims identify no assignee, NDA holder, licensee, ANDA applicant, district-court case, Patent Trial and Appeal Board proceeding, or settlement.
A complete competitive assessment would distinguish among:
- The patent owner and its licensees.
- The company developing the ErbB2 inhibitor.
- ANDA applicants.
- Formulation-development partners.
- Contract manufacturers using spray drying.
- Companies developing alternative polymers or non-amorphous formulations.
The relevant competitive risk is formulation substitution rather than biosimilar competition. The most direct alternatives are crystalline API products, amorphous dispersions using polymers other than PVP-VA, and non-spray-dried dispersions.
What generic launch scenarios exist?
| Scenario |
Likely patent issue |
Commercial implication |
| Same API, amorphous PVP-VA dispersion |
Direct claim 1 exposure |
High litigation risk |
| Same API, PVP-VA but crystalline API |
Possible claim 1 noninfringement |
Requires solid-state proof |
| Same API, different polymer |
Likely avoids claim 1 |
Formulation and bioequivalence work required |
| Same API, spray-dried with PVP-VA |
Claim 24 exposure |
Process discovery risk |
| Same API, tablet with sodium bicarbonate |
Claims 18 and 19 exposure |
Separate formulation risk |
| Same API, non-tablet dosage form |
May avoid tablet claims |
Claims 1 and 7 remain relevant |
| Same API, different indication |
May avoid claim 23 |
Product and label strategy matters |
| Same API, no FDA-listed patent |
No Paragraph IV certification for this patent |
Other patents may control launch |
The most effective design-around strategy would generally replace PVP-VA, avoid the claimed amorphous state, or use a process that does not dissolve both API and polymer before spray drying. Each route creates technical, stability, dissolution, and regulatory tradeoffs.
Key Takeaways
- U.S. Patent 9,457,093 is primarily a formulation and process patent.
- Claim 1 requires amorphous specified quinazoline API dispersed with PVP-VA.
- The claims do not establish broad protection for the API molecule itself.
- Claims 2 through 6 create loading and amorphous-content fallback positions.
- Claims 7 through 22 cover tablets, excipient-defined formulations, and sodium-bicarbonate compositions.
- Claim 23 covers treatment of ErbB2-positive breast cancer using the protected dispersion.
- Claim 24 covers co-dissolution followed by spray drying.
- Generic risk is highest for an amorphous PVP-VA product and lower for a different-polymer or crystalline formulation.
- Orange Book status, expiration, assignee, litigation, licensing, and settlement status are not established by the supplied claims.
- Biosimilar competition is not the relevant pathway because the claimed product is a small-molecule drug.
FAQs
Is PVP-VA the same as copovidone for infringement purposes?
PVP-VA generally refers to copovidone, a vinylpyrrolidone-vinyl acetate copolymer. Chemical identity, grade, composition, and claim construction determine whether a commercial copovidone product falls within the claim.
Can a crystalline formulation avoid U.S. Patent 9,457,093?
A genuinely crystalline formulation would have a strong noninfringement position against claims requiring amorphous API. The product would still require review against other patents and against any claim construction treating the formulation as containing an amorphous fraction.
Does claim 24 cover every spray-dried formulation?
No. Claim 24 requires dissolving both the active ingredient and PVP-VA in a suitable solvent and then spray drying the feed solution. A spray-drying process that does not meet those steps may avoid literal infringement.
Can a formulation using HPMC-AS instead of PVP-VA infringe claim 1?
Claim 1 expressly requires PVP-VA. A formulation using only HPMC-AS would generally have a noninfringement position under the claim’s literal language, subject to any applicable doctrine-of-equivalents analysis.
Is the patent relevant to biosimilar developers?
No. The claimed compound is a small molecule. Competitive products would typically be evaluated under the ANDA framework or another small-molecule regulatory pathway, not the biosimilar pathway.
References
-
United States Patent and Trademark Office. (2016). U.S. Patent No. 9,457,093, claims 1-24.
-
35 U.S.C. § 112. Patent application requirements.
-
35 U.S.C. § 154. Contents and term of patents; provisional rights.
-
35 U.S.C. § 156. Extension of patent term.
-
35 U.S.C. § 271. Infringement of patent.
-
35 U.S.C. § 271(e)(2). Infringement relating to abbreviated new drug applications.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
